AstraZeneca Annual Report and Form 20-F Information 2011

More documents

Recommendations

Info

Financial Statements4 ReservesSharepremiumaccount$mCapitalredemptionreserve$mOtherreserves$mProfitand lossaccount$mAt beginning of year 2,672 107 3,020 13,677 19,476 22,927Profit for the year – – – 2,961 2,961 2,043Dividends – – – (3,752) (3,752) (3,494)Amortisation of loss on cash flow hedge – – – 2 2 1Share-based payments – – (37) – (37) 98Share repurchases – 32 – (6,015) (5,983) (2,591)Issue of AstraZeneca PLC Ordinary Shares 406 – – – 406 492At end of year 3,078 139 2,983 6,873 13,073 19,476Distributable reserves at end of year – – 1,841 6,873 8,714 15,5182011Total$m2010Total$mAs permitted by section 408(4) of the Companies Act 2006, the Company has not presented its own profit and loss account.At 31 December 2011, $6,873m (31 December 2010: $13,677m) of the profit and loss account reserve was available for distribution. Includedin other reserves is a special reserve of $157m, arising on the redenomination of share capital in 1999.Included within other reserves at 31 December 2011 is $1,142m (31 December 2010: $1,179m) in respect of cumulative share-based paymentawards. These amounts are not available for distribution.5 Reconciliation of movement in shareholders’ fundsAt beginning of year 19,828 23,290Net profit for the financial year 2,961 2,043Dividends (3,752) (3,494)Amortisation of loss on cash flow hedge 2 1Share-based payments (37) 98Issue of AstraZeneca PLC Ordinary Shares 409 494Repurchase of AstraZeneca PLC Ordinary Shares (6,015) (2,604)Net decrease in shareholders’ funds (6,432) (3,462)Shareholders’ funds at end of year 13,396 19,8282011$m2010$mDetails of dividends paid and payable to shareholders are given in Note 21 to the Group Financial Statements on page 170.6 Share capitalAllotted, called-up and fully paidIssued Ordinary Shares ($0.25 each) 323 352Redeemable Preference Shares (£1 each – £50,000) – –323 3522011$m2010$mAt 31 December 2011, 1,292,355,052 Ordinary Shares were in issue.The Redeemable Preference Shares carry limited class voting rights and no dividend rights. This class of shares is capable of redemption at parat the option of the Company on the giving of seven days’ written notice to the registered holder of the shares.The movements in share capital during the year can be summarised as follows:No. of shares (m) $mAt 1 January 2011 1,409 352Issues of shares 11 3Repurchase of shares (128) (32)At 31 December 2011 1,292 323Share repurchasesDuring the year, the Company repurchased 128m Ordinary Shares at an average price of 2932 pence per share (2010: 54m Ordinary Shares atan average price of 3111 pence per share).Share schemesA total of 11m Ordinary Shares were issued during the year in respect of share schemes. Details of movements in the number of Ordinary Sharesunder option are shown in Note 24 to the Group Financial Statements; details of options granted to Directors are shown in the Directors’Remuneration Report.Shares held by subsidiariesNo shares in the Company are held by subsidiaries.196 Financial StatementsAstraZeneca Annual Report and Form 20-F Information 2011
7 Litigation and environmental liabilitiesIn addition to those matters disclosed below, there are other cases where the Company is named as a party to legal proceedings. Theseinclude the Seroquel product liability litigation; the Seroquel Attorney General commercial litigation; the Nexium product liability litigation;and the Symbicort freedom to operate lawsuit (Accuhale LLC v. AstraZeneca) each of which are described more fully in Note 25 to the GroupFinancial Statements.Foreign Corrupt Practices ActIn connection with an investigation into Foreign Corrupt Practices Act issues in the pharmaceutical industry, AstraZeneca has received inquiriesfrom the US Department of Justice and the SEC regarding, among other things, sales practices, internal controls, certain distributors andinteractions with healthcare providers in several countries. AstraZeneca is cooperating with these inquiries. AstraZeneca is investigatingindications of inappropriate conduct in certain countries, including China.European Commission investigationThe European Commission investigation into alleged practices regarding Nexium and alleged breaches of EU competition laws, which wascommenced in November 2010, remains pending.European Commission caseAstraZeneca is awaiting a ruling on the cross-appeals from the General Court of the EU’s judgment regarding the European Commission’s2005 Decision fining AstraZeneca €60m (reduced to €52.5m by the General Court) for abuse of a dominant position regarding omeprazole.An oral hearing took place on 12 January 2012.Dutch Competition Authority investigationThe Dutch National Competition Authority (NMa) investigation into alleged practices regarding Nexium and alleged breaches of both Dutch andEU competition laws is ongoing. In December 2011, the investigation team issued a report alleging foreclosure of generic versions of certainProton Pump Inhibitors. The file has now been passed to the Legal Department of the NMa.OtherThe Company has guaranteed the external borrowing of a subsidiary in the amount of $288m.8 Statutory and other informationThe Directors were paid by another Group company in 2011 and 2010.Financial StatementsAstraZeneca Annual Report and Form 20-F Information 2011 Financial Statements 197
Page 1 and 2:
healthAstraZeneca Annual Reportand
Page 3 and 4:
Financial summary$33.6bnSales down
Page 5 and 6:
China: We announcedour decision to
Page 7 and 8:
OverviewOperational overview7979 pr
Page 9 and 10:
Chairman’s StatementI would like
Page 11 and 12:
Chief Executive Officer’s ReviewA
Page 13 and 14:
The process of getting a drug to ma
Page 15 and 16:
OverviewnovationInnovation drives p
Page 17 and 18:
Our Strategy and PerformanceMore pe
Page 19 and 20:
Using the full range of innovative
Page 21 and 22:
Our strategyMissionto make the most
Page 23 and 24:
Our strategic priorities to 2014Our
Page 25 and 26:
Our performance in 2011Our performa
Page 27 and 28:
Business shapePeopleResponsible bus
Page 29 and 30:
Strategy and PerformanceaborationIm
Page 31 and 32:
Delivering our strategyOur strategy
Page 33 and 34:
Development projects20112010 129342
Page 35 and 36:
Investing in capabilitiesA core com
Page 37 and 38:
Patent expiries for our key markete
Page 39 and 40:
our Established Markets footprint i
Page 41 and 42:
Product qualityWe are committed to
Page 43 and 44:
We have a global approach, supporte
Page 45 and 46:
ComplianceWe ensure a culture of et
Page 47 and 48:
tegrityBusiness ReviewWe are dedica
Page 49 and 50:
Delivering our strategyResponsible
Page 51 and 52:
India has the fastest growing numbe
Page 53 and 54:
ProtestsAstraZeneca acknowledges th
Page 55 and 56:
Also in 2011, the DIHR in collabora
Page 57 and 58:
healthcollaborationRaising breast c
Page 59 and 60:
Pipeline by Therapy Area at 31 Dece
Page 62 and 63:
Therapy Area ReviewIn September, we
Page 64 and 65:
Therapy Area ReviewGastrointestinal
Page 66 and 67:
Therapy Area ReviewInfectionTherapy
Page 68 and 69:
Therapy Area ReviewIn the pipelineI
Page 70 and 71:
Therapy Area ReviewOur financial pe
Page 72 and 73:
Therapy Area ReviewOncologyTherapy
Page 74 and 75:
Therapy Area Reviewendpoints of pro
Page 76 and 77:
Therapy Area ReviewOur financial pe
Page 78 and 79:
healthinnovationReducing the number
Page 80 and 81:
Geographical ReviewUSAstraZeneca is
Page 82 and 83:
Geographical ReviewEmerging Markets
Page 84 and 85:
Disciplined execution of our strate
Page 86 and 87:
Financial ReviewMeasuring performan
Page 88 and 89:
Financial ReviewResults of operatio
Page 90 and 91:
Financial ReviewFinancial position
Page 92 and 93:
Financial ReviewCapitalisation and
Page 94 and 95:
Financial ReviewResults of operatio
Page 96 and 97:
Financial ReviewSensitivity analysi
Page 98 and 99:
Financial Reviewover the performanc
Page 100 and 101:
healthcollaborationFighting the ris
Page 102 and 103:
Board of Directors and Senior Execu
Page 104 and 105:
Board of Directors and Senior Execu
Page 106 and 107:
Corporate Governance ReportOperatio
Page 108 and 109:
Corporate Governance ReportThe Boar
Page 110 and 111:
Corporate Governance ReportDuring 2
Page 112 and 113:
Corporate Governance ReportBusiness
Page 114 and 115:
Corporate Governance ReportPolitica
Page 116 and 117:
Directors’ Remuneration ReportDav
Page 118 and 119:
Directors’ Remuneration ReportVar
Page 120 and 121:
Directors’ Remuneration ReportAdd
Page 122 and 123:
Directors’ Remuneration ReportSum
Page 124 and 125:
Directors’ Remuneration ReportSum
Page 126 and 127:
Directors’ Remuneration ReportIn
Page 128 and 129:
Directors’ Remuneration ReportPer
Page 130 and 131:
Directors’ Remuneration ReportGai
Page 132 and 133:
RiskManagement reporting and assura
Page 134 and 135:
RiskCommercialisation and business
Page 136 and 137:
RiskCommercialisation and business
Page 138 and 139:
RiskSupply chain and delivery risks
Page 140 and 141:
RiskEconomic and financial risks co
Page 142 and 143:
Financial StatementsPreparation of
Page 144 and 145:
Financial StatementsConsolidated St
Page 146 and 147:
Financial StatementsConsolidated St
Page 148 and 149: Financial StatementsGroup Accountin
Page 150 and 151: Financial StatementsProperty, plant
Page 152 and 153: Financial StatementsNotes to the Gr
Page 154 and 155: Financial Statements3 Finance incom
Page 156 and 157: Financial Statements4 Taxation cont
Page 158 and 159: Financial Statements6 Segment infor
Page 160 and 161: Financial Statements9 Intangible as
Page 162 and 163: Financial Statements10 Other invest
Page 164 and 165: Financial Statements15 Financial in
Page 166 and 167: Financial Statements15 Financial in
Page 168 and 169: Financial Statements18 Post-retirem
Page 170 and 171: Financial Statements18 Post-retirem
Page 172 and 173: Financial Statements20 Share capita
Page 174 and 175: Financial Statements23 Financial ri
Page 176 and 177: Financial Statements23 Financial ri
Page 178 and 179: Financial Statements24 Employee cos
Page 184 and 185: Financial Statements25 Commitments
Page 192 and 193: Financial Statements26 LeasesTotal
Page 194 and 195: Financial StatementsIndependent Aud
Page 196 and 197: Financial StatementsCompany Account
Page 200 and 201: Financial StatementsGroup Financial
Page 202 and 203: Development PipelineNCEsPhase III/R
Page 204 and 205: Development PipelineNCEsPhases I an
Page 206 and 207: Shareholder Information> For shares
Page 208 and 209: Shareholder InformationDocuments on
Page 210 and 211: Corporate InformationHistory and de
Page 212 and 213: GlossaryThe following abbreviations
Page 214 and 215: Index2011 performance summary 23Acc
Page 216: Contact informationRegistered offic
show all

AstraZeneca Annual Report and Form 20-F Information 2011

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?